Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
- 26 November 2007
- journal article
- research article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 178 (3) , 296-305
- https://doi.org/10.1503/cmaj.070693
Abstract
Background: Concern has been raised about the efficacy of antidepressant therapy for major depression in adults. We undertook a systematic review of published and unpublished clinical trial data to determine the effectiveness and acceptability of paroxetine. Methods: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register, the Cochrane Central Register of Controlled Trials, the GlaxoSmithKline Clinical Trial Register, MEDLINE and EMBASE up to December 2006. Published and unpublished randomized trials comparing paroxetine with placebo in adults with major depression were eligible for inclusion. We selected the proportion of patients who left a study early for any reason as the primary outcome measure because it represents a hard measure of treatment effectiveness and acceptability. Results: We included in our review 29 published and 11 unpublished clinical trials, with a total of 3704 patients who received paroxetine and 2687 who received with placebo. There was no difference between paroxetine and placebo in terms of the proportion of patients who left the study early for any reason (random effect relative risk [RR] 0.99, 99% confidence interval [CI] 0.88–1.11). Paroxetine was more effective than placebo, with fewer patients who did not experience improvement in symptoms of at least 50% (random effect RR 0.83, 99% CI 0.77–0.90). Significantly more patients in the paroxetine group than in the placebo group left their respective studies because of side effects (random effect RR 1.77, 95% CI 1.44–2.18) or experienced suicidal tendencies (odds ratio 2.55, 95% CI 1.17–5.54). Interpretation: Among adults with moderate to severe major depression in the clinical trials we reviewed, paroxetine was not superior to placebo in terms of overall treatment effectiveness and acceptability. These results were not biased by selective inclusion of published studies.This publication has 32 references indexed in Scilit:
- Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant ActionArchives of General Psychiatry, 2006
- Efficacy of antidepressants in adultsBMJ, 2005
- The Case for Practical Clinical Trials in PsychiatryAmerican Journal of Psychiatry, 2005
- Suicide, depression, and antidepressantsBMJ, 2005
- Explanatory and pragmatic attitudes in therapeutical trialsPublished by Elsevier ,2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- The antidepressant debateThe British Journal of Psychiatry, 2002
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold DepressionsThe World Journal of Biological Psychiatry, 2002
- Issues in the use of change scores in randomized trialsJournal of Clinical Epidemiology, 1989